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DOI: 10.1016/j.ajpath.2011.12.005This Month in AJPDefining Age-Dependent Biomarkers in the
CSF Proteome
To achieve success with diagnostic assays of cerebro-
spinal fluid (CSF) biomarkers in age-related neurodegen-
erative diseases, the nature of the CSF proteome in nor-
mal aging must be understood. Baird et al (Am J Pathol
2012, 180:446–456) used a novel proteomic technology
(SOMAmer) to quantify hundreds of CSF proteins from 90
cognitively normal adults (aged 21 to 85 years). They
detected 248 proteins with signals greater than twofold
over background. Several novel correlations indicated
that both inflammation and response to injury in the cen-
tral nervous system may increase with age. Such a bio-
marker profile, if validated, could thus be useful in studies
of normal and pathological central nervous system aging.
Inducing Gut Barrier Maturation with Probiotic
Bacteria
Impaired intestinal barrier function has been implicated in
the pathogenesis of infectious enteritis, inflammatory bowel
disease, and necrotizing enterocolitis. Patel et al (Am J
Pathol 2012, 180:626–635) report that commensal bacte-
rial colonization induces intestinal barrier function matura-
tion by promoting claudin 3 expression, a key component of
tight junctions. Neonatal mice raised on antibiotics or those
lacking MyD88 exhibited impaired barrier function and de-
creased claudin 3 expression. Enteral administration of ei-
ther live or heat-killed preparations of the probiotic Lacto-
bacillus rhamnosus GG accelerated intestinal barrier
maturation and induced claudin 3 expression while live L.
rhamnosus GG increasedmortality. These data indicate that
probiotic administration can accelerate the maturation of
both claudin 3 protein expression and intestinal barrier
function in an immature gut lacking commensal bacteria,
possibly preventing intestinal inflammatory diseases.
A Novel Murine Model of Myasthenia Gravis
Myasthenia gravis (MG) is caused by autoantibodies
against postsynaptic membranes at neuromuscular junc-
tions (NMJs). However, antibodies against muscle-specific
kinase (MuSK) do not act via the complement pathway. To
investigate the pathophysiology of MuSK-MG, Mori et al
(Am J Pathol 2012, 180:798–810) injected MuSK protein
into mice deficient in complement protein C5. MuSK-in-
jected mice developed severe muscle weakness, with an
electromyographic pattern similar to that observed in MG
patients. Morphological and functional defects in NMJs
confirmed that complement activation is not necessary forMuSK-MG onset. Furthermore, MuSK-injected mice exhib-
ited a loss of acetylcholine receptor expression, as well as
reduced size of motor terminals apposing acetylcholine re-
ceptor clusters at NMJs. Thus, disruption of MuSK activity
by autoantibodies triggers MG. This experimental MG
model could be useful in developing appropriate medica-
tions for the treatment of MuSK-MG in humans.
Can Cells Express Both Hematopoietic and
Mesenchymal Markers in Normal Bone Marrow?
Bone marrow (BM) fibrosis is a feature of severe hyper-
parathyroidism, and mice overexpressing constitutively
active parathyroid hormone (PTH)/PTH-related peptide
receptors in osteoblasts (PPRTg) exhibit BM fibrosis. To
gain insights into the complexity of the BM stroma, Ohishi
et al (Am J Pathol 2012, 180:811–818) generated a dou-
ble-mutant mouse that also expresses GFP under the
control of the type I collagen promoter (PPRTg/GFP). A
GFPCD45 cell population was identified in the BM of
both PPRTg/GFP and control animals, though it was
expanded in PPRTg/GFP mice. The existence of cells
expressing both type I collagen (ie, GFP) and CD45 in the
adult BM was confirmed by IHC and FACS. mRNA expres-
sion of type I collagen and PTH/PTH-related peptide recep-
tor and receptor activator for NF-B was confirmed, further
supporting features of both mesenchymal and hematopoi-
etic lineages. These findings indicate that the BM is a per-
missive microenvironment for the differentiation of fibrocyte-
like cells and raise the possibility that these cells could
contribute to the pathogenesis of BM fibrosis.
FOXA1 and Castrate-Resistant Prostate Cancer
Forkhead box protein A1 (FOXA1) modulates the transacti-
vation of steroid hormone receptors and thus may influence
tumor growth and hormone responsiveness in prostate can-
cer. Gerhardt et al (Am J Pathol 2012, 180:848–861) inves-
tigated the correlation of FOXA1 expression with various
disease parameters in a large cohort of prostate cancer
patients at different disease stages. FOXA1 expression in-
creased from primary prostate carcinomas of the peripheral
zone and metastases to castration-resistant prostate can-
cer, reflected by a correlation with higher Gleason scores,
higher tumor stages, and faster biochemical disease pro-
gression (the last particularly in cases with lower androgen
receptor levels). siRNA knockdown of FOXA1 induced de-
creased cell proliferation and migration, and full in vitro tu-
morigenicity of the androgen-dependent prostate cancer
cell line LNCaP required FOXA1 expression. Thus, FOXA1
represents a novel mechanism of castration resistance and
a novel candidate therapeutic target.
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